everyone who was hanging around for the 'big
announcement' will exit and the stock will have to trade based
on the numbers - could be a little overvalued - huge
debt load etc good long term hold though
I do not know your understanding of reported
restenosis rates, but both GFX and Nir have performed
EQUIVALENCE trials to J&J Palmaz-Schatz and demonstrated only
that, equivalence. In fact, Ave's Micro stents have had
several abstracts demonstrating equivalent initial
results, but a greater late loss index than Palmz-Schatz.
The etiology of this could be a chronic recoil due to
poor radial strength, but that's speculative...the
results are not.
lawsuits are a strategic
tactic used frequently by medical device companies,
especially patent infringement suits. As a rule, patents are
written as broadly as possible, and patent suits then
clarify and define what is actually accepted as the legal
interpretation of the claims presented in the patent. At any
time a medical company will have at least one and more
usually several infringement suits going, either as
plaintiff or as defendant.
Except in very blatant
infringement the exact outcome of a lawsuit is hard to
predict, and will take a long time to go through
deposition and disclosure. Unless a court issues an
injunction (not a very common action) the device will
continue being sold through the process.
(though I don't have figures to back this up) that most
suits are actually settled out of court, either with a
settlement or some sort of licensing agreement.
Possible mergers are never a problem, it's the
actual mergers that cause problems. Don't plan on
corporate mergers as they seem to happen at an extremely
random rate. If BSX can empty out some of the warehouses
filled with NIR stents, I expect the stock will be
upgraded. But that will take time to happen, next week is
too soon. Try the middle of Fall.
You are both full of shit and a lier, and as a
friend of BSX I'm glad you were admonished in the last
post. I have worked with BSX for over a decade and know
all top management (the same people who would not
recognize you in roon) personally There are several very
important issues the company has legitimate concerns about
that affect their and your financial viability.
They clearly had no choice but to overpay for Scneider
to avoid patent infringement judgements that would
have ruined them.
2- It is disgraceful that the
leading balloon company in the world should be so late to
market with a stent- and then it is a stent developed by
another company that they are paying off very
3-All labs already have the shelves stocked with the
competitors product and they are not going to place big
orders for your stents until you convincingly prove
Medinaol and BSX management are not getting along and
Medinol has their name prominently displayrd on all your
marketing material and actual product for the Nir. Goldman
Sachs is working with Medinol on an IPO. What happens
to the wonderful BSX Nir stent when Medinol
establishes their own presence.
4- Many of the excellant
men and women who built Scimed into a great company
before a dweeb such as yourself worked for them are no
longer with the company.
5-Major investments in
rotoblater and IVUS will never return the money spent on
6 The sales force isn't what it used to be. Many
excellant sales people have moved into middle management
and been replaced by weaker players and some have
moved on to other companies, including AVE.
up and keep selling big guy because this companies
stock price is in for a fall and you'll have to earn
you're money from sales and not stock options(although
it is unlikely you're important enough to have any).
Good call, Jock. Further to those fine points,
J&J has licensed two companies to date, Cook and
Medtronic. Strategically, these were good moves for J&J
because 1) J&J received technology in a cross-license
(marker bands from Cook, and Wiktor from Medtronic so
they could practice Crossflex), and 2) J&J considered
Cook and Medtronic non-competitive in the long
J&J is much more concerned about Guidant and BSX as
competitors, as they should, but law suits are decided by
average guys in court rooms, a risky business. It is
difficult for patent attorneys, engineers, and business
pros to sort through patent complexities; now how
would you like a panel of twelve amateurs to digest
these complex engineering subtleties and make a billion
The result is settlements. Two
companies typically go to court and battle it out, see how
it goes, weigh the strength of your opponents
position, and settle on more or less favorable terms
depending on how you view the court room drama. BSX will
pay a royalty to J&J. How big a royalty? It depends.
$700-800M in stent sales over next 9
If that's your expectation, lookout below.
afraid NIR is going to be BIG disappointment. It
get a relatively modest share of the stent business
and is definitely not going to significantly erode
Possible MDT/AVEI merger will mean big
trouble for BSX and GDT.
The Radius has been received well. period. My
friends have told me of one facility which ONLY used
Radius all week. Nothing else. There is a training issue
with deployment but jumping 5-10mm? Come on, accept
competition gracefully. I guess an improperly deployed stent
can move slightly, but the catheter, or more
importantly the markerbands appear to "jump". The combination
of balloon and self expanding stent leaves me very
optimistic for this stock for the next 3q
AVE is shooting blanks.
What is the NIR
AVE is an articulated, welded-wire
NIR is a closed-cell flexible stent.
covered by a US patent issued to Medinol, licensed to
AVE is doing what most frightened companies do when
there appears competition. It won't work!
most likely counter sue citing AVE's effort to
prohibit them from doing business.
A lawsuit like
this will make AVE harder to sell/merge with another
company. The suit will be dropped or rejected.
not sell your BSX stock!!!